Nature’s own defense molecules move closer to the cancer clinic

Some of nature's most effective defense systems may one day help doctors treat cancer. A new review published in the Chinese Journal of Natural Medicines highlights growing evidence that naturally derived oncolytic peptides, found in organisms ranging from bees and frogs to insects and humans, could become a new generation of cancer therapeutics.

Cancer treatment has advanced rapidly in recent years, yet many patients still face a major challenge: tumors can become resistant to existing therapies. Researchers are therefore searching for treatment strategies that work through entirely different mechanisms. Oncolytic peptides have attracted increasing attention because they attack one of cancer cells' most fundamental vulnerabilities, namely the structure of their outer membranes. This approach may make it more difficult for tumors to develop resistance compared with therapies that target a single molecule or signaling pathway.

The review traces the discovery of numerous naturally occurring oncolytic peptides from diverse biological sources, including bee venom, amphibian skin secretions, insect-derived peptides, and human host-defense molecules. Many of these compounds have demonstrated the ability to selectively damage cancer cells while causing comparatively less harm to normal tissues. Beyond directly killing tumor cells, some oncolytic peptides appear capable of activating the body's immune system. When cancer cells are destroyed, they can release signals that help immune cells recognize and attack remaining tumors. This dual action, combining direct tumor destruction with immune activation, has positioned oncolytic peptides as promising partners for modern cancer immunotherapies.

The authors also review recent efforts to overcome longstanding challenges in peptide drug development. Natural peptides can be unstable in the bloodstream and may have limited ability to reach tumors efficiently. To address these issues, researchers have developed new peptide-engineering strategies, nanoparticle delivery systems, hydrogels, and other technologies designed to improve stability, safety, and therapeutic performance. Importantly, the field is beginning to move beyond laboratory studies. Several naturally derived oncolytic peptides and peptide-based formulations have entered clinical evaluation, where early findings suggest favorable safety profiles and potential therapeutic benefits. Researchers are also exploring how these agents can be combined with immune checkpoint inhibitors, chemotherapy, radiotherapy, and other treatment modalities to improve outcomes for patients with difficult-to-treat cancers.

The authors conclude that naturally derived oncolytic peptides represent a rapidly evolving area of cancer research. As advances in peptide engineering, drug delivery, and immunotherapy continue to converge, these molecules may help translate nature's defense mechanisms into future cancer treatments.

The full article is available here: https://doi.org/10.1016/S1875-5364(26)61185-5Get rights and content